Investment bank Evercore ISI initiated coverage of Guardant Health, assigning an Outperform rating with a $60 price target. Evercore projects over 20% annual top-line growth through 2027, driven by liquid biopsy therapy selection products and the emerging TissueNext platform. The firm highlights the potential of Guardant's Reveal minimal residual disease assay and the Shield multi-cancer early detection test, the latter considered a strategic entry into a multibillion-dollar MCED market, albeit currently dilutive. Guardant’s core operations are anticipated to reach break-even by late 2024, with full profitability including Shield by 2028. Risks include therapy selection market dynamics and Reveal assay clinical data outcomes.